Targeting PCSK9 increased tumor cell MHC I expression, promoted CD8+ T cell tumor infiltration and cytotoxicity and potentiated the effects of PD-1/PD-L1 checkpoint blockade. This evidence concerns the gene CD8A and neoplasm.